228 related articles for article (PubMed ID: 17972922)
21. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
22. Development of an in vitro cell culture assay system for measuring the activation of a neighbouring gene by the retroviral vector.
Hong Y; Yu SS; Yoon NK; Kang SJ; Lee JT; Kim S; Kim JM; Lee K; Jang JW; Kim S
J Gene Med; 2008 Aug; 10(8):847-54. PubMed ID: 18563862
[TBL] [Abstract][Full Text] [Related]
23. Murine hematopoietic stem cell transduction using retroviral vectors.
Modlich U; Schambach A; Li Z; Schiedlmeier B
Methods Mol Biol; 2009; 506():23-31. PubMed ID: 19110617
[TBL] [Abstract][Full Text] [Related]
24. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
25. Concise review: managing genotoxicity in the therapeutic modification of stem cells.
Baum C; Modlich U; Göhring G; Schlegelberger B
Stem Cells; 2011 Oct; 29(10):1479-84. PubMed ID: 21898683
[TBL] [Abstract][Full Text] [Related]
26. No evidence of clonal dominance in primates up to 4 years following transplantation of multidrug resistance 1 retrovirally transduced long-term repopulating cells.
Bozorgmehr F; Laufs S; Sellers SE; Roeder I; Zeller WJ; Dunbar CE; Fruehauf S
Stem Cells; 2007 Oct; 25(10):2610-8. PubMed ID: 17615269
[TBL] [Abstract][Full Text] [Related]
27. Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies.
Dunbar CE
Ann N Y Acad Sci; 2005 Jun; 1044():178-82. PubMed ID: 15958711
[TBL] [Abstract][Full Text] [Related]
28. Rapid detection of retroviral vector integration sites in colony-forming human peripheral blood progenitor cells using PCR with arbitrary primers.
Gentner B; Laufs S; Nagy KZ; Zeller WJ; Fruehauf S
Gene Ther; 2003 May; 10(9):789-94. PubMed ID: 12704418
[TBL] [Abstract][Full Text] [Related]
29. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
30. Transduction of hematopoietic stem cells with a retroviral vector expressing the neomycin phosphotransferase gene.
Link CJ; Seregina T; Edleman M; Young WB; Burt RK; Kisselev S
Bone Marrow Transplant; 2003 Aug; 32 Suppl 1():S33-5. PubMed ID: 12931238
[TBL] [Abstract][Full Text] [Related]
31. RTCGD: retroviral tagged cancer gene database.
Akagi K; Suzuki T; Stephens RM; Jenkins NA; Copeland NG
Nucleic Acids Res; 2004 Jan; 32(Database issue):D523-7. PubMed ID: 14681473
[TBL] [Abstract][Full Text] [Related]
32. Mutational effects of retrovirus insertion on the genome of V79 cells by an attenuated retrovirus vector: implications for gene therapy.
Themis M; May D; Coutelle C; Newbold RF
Gene Ther; 2003 Sep; 10(19):1703-11. PubMed ID: 12923569
[TBL] [Abstract][Full Text] [Related]
33. Integration site selection by retroviruses.
Cereseto A; Giacca M
AIDS Rev; 2004; 6(1):13-21. PubMed ID: 15168737
[TBL] [Abstract][Full Text] [Related]
34. NOD/SCID repopulating cells contribute only to short-term repopulation in the baboon.
Mezquita P; Beard BC; Kiem HP
Gene Ther; 2008 Nov; 15(21):1460-2. PubMed ID: 18563183
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy in retrovirally modified haematopoietic cell therapy.
Li Z; Modlich U; Baum C
Best Pract Res Clin Haematol; 2004 Sep; 17(3):493-503. PubMed ID: 15498719
[TBL] [Abstract][Full Text] [Related]
36. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
[TBL] [Abstract][Full Text] [Related]
37. A review of gene therapy for haematological disorders.
Nathwani AC; Davidoff AM; Linch DC
Br J Haematol; 2005 Jan; 128(1):3-17. PubMed ID: 15606545
[TBL] [Abstract][Full Text] [Related]
38. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
Westwood JA; Murray WK; Trivett M; Shin A; Neeson P; MacGregor DP; Haynes NM; Trapani JA; Mayura-Guru P; Fox S; Peinert S; Honemann D; Prince HM; Ritchie D; Scott AM; Smyth FE; Smyth MJ; Darcy PK; Kershaw MH
Gene Ther; 2008 Jul; 15(14):1056-66. PubMed ID: 18369322
[TBL] [Abstract][Full Text] [Related]
39. The use of retroviral vectors for gene transfer into hematopoietic stem cells.
Holst J; Rasko JE
Methods Enzymol; 2006; 420():82-100. PubMed ID: 17161695
[No Abstract] [Full Text] [Related]
40. Pois(s)on--it's a question of dose..
Fehse B; Kustikova OS; Bubenheim M; Baum C
Gene Ther; 2004 Jun; 11(11):879-81. PubMed ID: 15057265
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
